相关临床试验
457
265 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1993
进行中（未招募）
265
58.0%
Approved For Marketing
1
0.2%
已完成
156
34.1%
No Longer Available
1
0.2%
招募中
3
0.7%
终止
23
5.0%
撤回
6
1.3%
暂无批准数据
- Immunocine Cancer Center has appointed Stephen J. Noga, M.D., Ph.D., a former Johns Hopkins faculty member with over three decades of oncology experience, as its new Chief Medical Officer. - Dr. Noga's early doctoral research contributed to the identification of dendritic cells, which are now central to Immunocine's personalized cancer immunotherapy platform. - In his new role, Dr. Noga will oversee medical operations and guide development of therapies that use a patient's own tumor tissue and dendritic cells to train the immune system against their cancer. - Dr. Noga previously held senior leadership roles at Takeda Oncology, Exact Sciences, and the University of Maryland Greenbaum Comprehensive Cancer Center.
- CHARM Therapeutics has appointed Dr. Erkut Bahceci as Chief Medical Officer following an $80 million Series B financing to advance its next-generation menin inhibitor for acute myeloid leukemia. - Dr. Bahceci brings over two decades of hematology and oncology experience, having led clinical development programs at major pharmaceutical companies including Takeda, Astellas, and Bristol-Myers Squibb. - The company's lead menin inhibitor, developed using its proprietary DragonFold platform, is designed to overcome resistance mutations and deliver deeper responses for AML patients. - Clinical development is expected to begin in 2026 with first-in-human studies under Dr. Bahceci's leadership.
- The new BrECADD chemotherapy regimen preserves fertility significantly better than the previous standard eBEACOPP treatment in advanced Hodgkin's lymphoma patients without compromising cure rates. - Three years post-treatment, 95% of women and 86% of men in the BrECADD group had normal hormone levels compared to 73% and 40% respectively in the eBEACOPP group. - The HD21 phase III trial involving over 1,500 participants across 233 centers in nine countries demonstrates BrECADD's superior fertility preservation, particularly benefiting male patients' chances of biological paternity. - BrECADD has become the new standard first-line treatment for patients wishing to have children at University Hospital Cologne and in current Onkopedia guidelines.
- A discrete choice experiment with 205 ALK+ NSCLC patients and 125 caregivers found that both groups overwhelmingly prioritized 3-year progression-free survival when making treatment decisions. - Patients were willing to trade 3.9-8.7% of 3-year PFS to reduce risks like cognitive/mood effects, abnormal lab results, and lung complications, while caregivers showed similar but not identical risk tolerance patterns. - The study revealed significant differences in how patients and caregivers perceive adverse events, with caregivers ranking lab abnormalities as a major concern due to potential dose reductions, while patients prioritized quality-of-life impacts like muscle pain. - Researchers emphasized the importance of including both patients and caregivers in treatment discussions, as they observe different aspects of the treatment experience and have varying priorities regarding benefit-risk trade-offs.
- A phase 3 clinical trial led by the University of Leeds demonstrated that a second stem cell transplant followed by ixazomib maintenance therapy extends myeloma remission by seven months compared to standard care. - The ACCoRd trial treatment protocol combines autologous stem cell transplantation with targeted drugs thalidomide, dexamethasone, and ixazomib, offering patients improved quality of life compared to chemotherapy or long-term steroid use. - Ixazomib works by preventing protein breakdown in myeloma cells, causing toxic buildup while allowing healthy cells to grow, presenting a promising alternative for patients eligible for a second bone marrow transplant.
- A novel triplet regimen of decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of advanced-phase CML patients. - The Phase II trial included patients with accelerated or myeloid blast-phase CML and Philadelphia chromosome-positive AML. - The combination therapy showed efficacy even in patients with prior therapies and high-risk cytogenetic or molecular features. - The observed side effects were consistent with previous studies of the individual drugs, including neutropenia, rash, and nausea.
